Inventiva (6IV) Stock Overview
A clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
6IV Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Inventiva S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €4.73 |
| 52 Week High | €6.15 |
| 52 Week Low | €3.15 |
| Beta | 0.95 |
| 1 Month Change | -10.34% |
| 3 Month Change | -6.25% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -22.45% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6IV | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -1.0% | 2.5% |
| 1Y | n/a | 2.4% | 8.8% |
Return vs Industry: Insufficient data to determine how 6IV performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how 6IV performed against the German Market.
Price Volatility
| 6IV volatility | |
|---|---|
| 6IV Average Weekly Movement | 9.1% |
| Biotechs Industry Average Movement | 9.2% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in DE Market | 13.8% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: 6IV's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine 6IV's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 84 | Andrew Obenshain | inventivapharma.com |
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. It also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis.
Inventiva S.A. Fundamentals Summary
| 6IV fundamental statistics | |
|---|---|
| Market cap | €842.45m |
| Earnings (TTM) | -€354.14m |
| Revenue (TTM) | €7.93m |
Is 6IV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6IV income statement (TTM) | |
|---|---|
| Revenue | €7.93m |
| Cost of Revenue | €0 |
| Gross Profit | €7.93m |
| Other Expenses | €362.06m |
| Earnings | -€354.14m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Sep 25, 2026
| Earnings per share (EPS) | -1.85 |
| Gross Margin | 100.00% |
| Net Profit Margin | -4,468.05% |
| Debt/Equity Ratio | -1,490.6% |
How did 6IV perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/14 09:40 |
| End of Day Share Price | 2026/04/13 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Inventiva S.A. is covered by 23 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Eliana Merle | Barclays |
| Edward Nash | Canaccord Genuity |
| Etzer Darout | Guggenheim Securities, LLC |